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Abstract
 
Relatively little is known about the pathway leading to the presentation of glycolipids by CD1
molecules. Here we show that the adaptor protein complex 3 (AP-3) is required for the efficient
presentation of glycolipid antigens that require internalization and processing. AP-3 interacts
with mouse CD1d, and cells from mice deficient for AP-3 have increased cell surface levels of
CD1d and decreased expression in late endosomes. Spleen cells from AP-3–deficient mice have
a reduced ability to present glycolipids to natural killer T (NKT) cells. Furthermore, AP-3–
deficient mice have a significantly reduced NKT cell population, although this is not caused by
self-tolerance that might result from increased CD1d surface levels. These data suggest that the
generation of the endogenous ligand that selects NKT cells may also be AP-3 dependent.
 
However, the function of MHC class II–reactive CD4
 
 
 
 T lymphocytes is not altered by AP-3
deficiency. Consistent with this divergence from the class II pathway, NKT cell development
and antigen presentation by CD1d are not reduced by invariant chain deficiency. These data
demonstrate that the AP-3 requirement is a particular attribute of the CD1d pathway in mice
and that, although MHC class II molecules and CD1d are both found in late endosomes or
lysosomes, different pathways mediate their intracellular trafficking.
Key words: intracellular localization • trafﬁcking • lipid antigen • lymphocyte selection • 
MHC II trafﬁcking pathway
 
Introduction
 
CD1 molecules are a third family of antigen-presenting
molecules. CD1a, CD1b, and CD1c present cell wall gly-
colipids from mycobacteria for host defense (1, 2) and
brain-derived glycolipids (3). CD1d presents glycolipids to
natural killer T (NKT) cells, a population of T lymphocytes
that may have important immune regulatory functions (4).
NKT cells typically have been defined as lymphocytes that
express both TCR and NK1.1, but much attention has
been focused on the NKT cell subset that in mice expresses
 
a TCR 
 
 
 
 chain encoded by a rearrangement of V
 
 
 
14 to
 
J
 
 
 
18 (formerly J
 
 
 
281). This rearrangement forms an invariant
CDR3
 
 
 
 region (V
 
 
 
14
 
i
 
) in these lymphocytes (5), and here
we refer to them as V
 
 
 
14
 
i
 
 NKT cells in order to designate
this subset more precisely. Many V
 
 
 
14
 
i
 
 NKT cells are self-
reactive to APC-expressing mouse CD1d (mCD1d) (6–8);
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–
 
d
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lysozyme; LDLr, low density lipoprotein receptor; NKT, natural killer T.T
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this presumably requires presentation by mCD1d of an en-
dogenous, self-glycolipid ligand. Furthermore, nearly all of
them show enhanced responses when mCD1d presents
the synthetic phytosphingolipid, 
 
 
 
–
 
d
 
-galactosyl ceramide
(
 
 
 
GalCer) (9, 10). 
 
 
 
GalCer was obtained from an extract
of a marine sponge as a result of a screen for compounds
that could prevent the metastases of transplanted tumors to
the livers of mice (11). This glycolipid belongs to the cate-
gory of glycosphingolipids that include the gangliosides,
but the 
 
 
 
 anomeric linkage of the galactose to the lipid is
unusual, since nearly all glycosphingolipids have a 
 
 
 
 linkage
of the sugar to the lipid. Therefore, it is generally assumed
that 
 
 
 
GalCer is not a natural ligand for V
 
 
 
14
 
i
 
 NKT cells,
but the structure of this natural ligand remains to be deter-
mined. The pathway leading to the presentation of gly-
colipid antigens by CD1d molecules is not well defined.
Furthermore, although both CD1 molecules and MHC
class II molecules are found in endosomes, features required
for proper CD1 localization and antigen presentation that
distinguish it from MHC class II molecules have not been
identified. CD1b, CD1c, and CD1d all have a tyrosine-
containing sequence in their cytoplasmic tails that mediates
their localization to various types of endosomal compart-
ments (12). Mice bearing a germ line deletion of the cyto-
plasmic tail of mCD1d have been generated, and APC
from these mice have a defect in glycolipid antigen presen-
tation (13). These mice also have a greatly reduced number
of V
 
 
 
14
 
i
 
 NKT lymphocytes, despite greater than normal
levels of surface mCD1d expression, strongly suggesting
that the natural ligand required for the selection or homeo-
stasis of these cells depends on the normal endosomal traf-
ficking of mCD1d. These findings do not, however, iden-
tify a particular role for early or late endosomes in mCD1d
antigen presentation.
Four AP complexes are known to bind to the tyrosine or
dileucine-containing sequence motifs in transmembrane
proteins in order to direct their selective localization to
subsets of endosomal compartments (14, 15). This suggests
that one or more of these could be involved in mCD1d
trafficking, but the role of these adaptors in antigen presen-
tation remains to be defined. AP-1 is important for the traf-
ficking of proteins from the trans-Golgi network to endo-
somes (16), and AP-2 is involved in the internalization of
membrane proteins to recycling compartments (17). Adap-
tor protein complex 3 (AP-3), by contrast, is involved in
the localization of membrane proteins to lysosomes, plate-
let-dense granules, and melanosomes (18). Each AP com-
plex is a heterotetramer. For example, the AP-3 complex
found in most cells is composed of 
 
 
 
3A, 
 
 
 
, 
 
 
 
3A, and 
 
 
 
3
subunits (19). Spontaneous mutants of the AP-3 
 
 
 
3A and 
 
 
 
subunits in mice were uncovered because of their effects on
coat color, although these animals also have defects in
platelets and other systems (15, 20). The 
 
 
 
3A mutants,
known as 
 
pearl
 
 mice, are considered a model for the Her-
mansky-Pudlak syndrome, which is characterized by mis-
regulation of the biogenesis/function of melanosomes, ly-
sosomes, and bleeding diathesis in these patients due to
 
defects in platelet dense granules (21). We have shown that
disaccharide analogs of 
 
 
 
GalCer, such as Gal(
 
 
 
1
 
→
 
2)
 
 
 
Gal-
Cer, require processing of their carbohydrate portion to
generate the antigenic monosaccharide 
 
 
 
GalCer. Lysoso-
mal enzymes mediate this antigen-processing event, and
mCD1d is found in lysosomes (22), but it is not known if
the mCD1d molecules in lysosomes are functional in anti-
gen presentation. To address this question, we have ana-
lyzed mCD1d mutants having alterations in the cytoplas-
mic tail, and additionally, we have focused on mice bearing
mutations in AP-3. The data define a role for AP-3 in
mCD1d antigen presentation, but not for MHC class II
presentation, and they strongly support the hypothesis that
mCD1d localization to late endosomes or lysosomes is re-
quired for both antigen presentation and development of
V
 
 
 
14
 
i
 
 NKT cells.
 
Materials and Methods
 
Mice. Pearl
 
 (
 
pe/pe
 
) mutant and heterozygous 
 
pe/
 
 
 
 mice on
the C57BL/6 background were a gift from Dr. Richard Swank
(Roswell Park Memorial Institute, Buffalo, NY). These mice
have a deletion in the COOH terminal region of the 
 
 
 
3A sub-
unit of the AP-3 adaptor, thereby creating a hypomorphic allele
(20). The 
 
 
 
3B protein, the neuronal form of 
 
 
 
3, is not affected
by this mutation (23). 
 
Pearl
 
 mice were bred in the vivarium of the
La Jolla Institute for Allergy and Immunology by mating het-
erozygous females (black coat) to homozygous males (gray coat).
The offspring were typed as 
 
pe/pe
 
 based on their gray coat color.
 
Mocha
 
 (
 
mh/mh
 
) mutant and heterozygous (
 
mh/
 
 
 
) mice are of
a mixed genetic background and were obtained from the
Jackson  Laboratory. C57BL/6, C57BL/6 RAG1
 
 
 
/
 
 
 
, 
 
Ii
 
 
 
/
 
 
 
(B6.129S6.litm1liz), and B6 CD45.1(B6.SJL-
 
Ptprca Pep3b
 
/BoyJ)
congenic mice were obtained from the Jackson Laboratory.
J
 
 
 
18
 
 
 
/
 
 
 
 (J
 
 
 
281
 
 
 
/
 
 
 
) mice were a gift from Dr. M. Taniguchi
(Chiba University, Chiba, Japan).
 
Cell Lines. 
 
B cell lymphoma A20 cells and V
 
 
 
14
 
i
 
 NKT cell
hybridomas 1.2, 1.4, 3C3, and 2C12 were described previously
(10, 24). The V
 
 
 
14
 
i
 
 NKT cell hybridomas share the V
 
 
 
14
 
i
 
 
 
 
 
chain, express different TCR 
 
 
 
 chains, and all have reactivity for
 
 
 
GalCer presented by mCD1d. The fetal skin dendritic cell
(FSDC) line was a gift from Dr. Paula Ricciardi-Castagnoli (Insti-
tuto Dermopatico dell’Immacolata, Istituto di Ricovero e Cura a
Carattere Scientifico, Rome, Italy) (25). Whole splenocytes and/
or DCs were prepared from 
 
pe/
 
 
 
, 
 
pe/pe
 
, B6, and 
 
Ii
 
 
 
/
 
 
 
 mice ac-
cording to procedures reported previously (10).
 
Generation of Cell Lines Expressing WT or Mutant mCD1d.
 
Primers were designed to contain 5
 
 
 
 BamHI or 3
 
 
 
 SalI sites to fa-
cilitate subcloning. To generate mouse CD1d (mCD1d)/a chi-
meras, in which the cytoplasmic tail and transmembrane region
are derived from CD1a, a chimeric oligonucleotide encoding aa
G271 to W279 of the mCD1d 
 
 
 
3 domain and aa V274 to S281
of the human CD1a transmembrane domain, 5
 
 
 
-GGAGGA-
CAGGATATCATCCTCTACTGGGAGCATCACAGTTCC-
3
 
 
 
, paired with an oligonucleotide from aa F307 to the stop
codon in the hCD1a cytoplasmic domain, 5
 
 
 
-GCGTCGACT-
TAACAGAAACAGCGTTTCCTGAACC-3
 
 
 
, were used to
amplify the transmembrane and cytoplasmic domains of hCD1a
from the plasmid 
 
 
 
H3M-CD1a (26, 27). The amplified fragment
was then paired with an oligonucleotide encompassing the NH
 
2
 
terminus of mCD1d, 5
 
 
 
-GCGGATCCTGTGTAGAACTCTG-T
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GCGCTATGCGG-3
 
 , to amply the ectodomain of mCD1d us-
ing pH ANeo-CD1.1 (28) as the PCR template. The mCD1d/b
construct was made in a similar fashion except that a PCR prod-
uct containing the transmembrane and cytoplasmic domains of
human CD1b was first amplified using an oligonucleotide encod-
ing aa G271 to W279 of the mCD1d  3 domain and aa I273 to
P281 of the transmembrane domain of human CD1b, 5 -GGAG-
GACAGGATATCATCCTCTACTGGAGAAACCCCACC-
3 , paired with an oligonucleotide from aa R312 to the stop
codon in the hCD1b cytoplasmic domain, 5 -GCGTCGACT-
CATGGGATATTCTGATATGACCGGCG-3 , using the plas-
mid  H3M-CD1b (26, 27) as the template. To make a chimera
containing the mCD1d ectodomain and transmembrane region
fused to the cytoplasmic tail of the low density lipoprotein recep-
tor (LDLr) chimera, called mCD1d/ldlr, total RNA from a
C57BL/6 mouse liver was extracted using a High Pure RNA kit
(Roche), and first strand cDNA was synthesized using a First-
Strand cDNA Synthesis kit (Amersham Biosciences) according
the manufacturers’ instructions. RT-PCR was then performed to
obtain the cytoplasmic domain of the mouse LDLr using a pair of
oligonucleotides encoding aa V299 to W308 of the transmem-
brane domain of mCD1d and the 5  portion of the cytoplasmic
domain of mLDLr, 5 -GTGGTGGGTGCTGTAGTCTAC-
TATATCTGGAGGAACTGGCGGCTGAAGAAC-3 , and the
3  end of the mLDLr cytoplasmic domain, 5 -GCGTCGACT-
CATGCCACATCGTCCTCCAGGC-3 . The amplified cyto-
plasmic fragment was then used as a 3  primer paired with the 5 
mCD1d primer to amplify the ectodomain and the transmem-
brane domain of mCD1d. These PCR products were cloned into
TOPO-pBlunt (Invitrogen), and all vector sequences were veri-
fied by dideoxynucleotide sequencing using an Applied Biosys-
tems Prism 310 genetic analyzer (PerkinElmer). The WT and
mutant mCD1d constructs were then digested with BamHI and
SalI and subcloned into pBabe/puro vector for retrovirus produc-
tion and transduction into A20 B lymphoma cells and FSDC cells
as described previously (29). After selection, the high-expressing
cells were selected by fluorescence-activated cell sorting using the
1B1 anti-mCD1d mAb (BD Biosciences).
Yeast Two-hybrid Assays. The constructs Gal4AD- 3A in the
pACTII (LEU2) plasmid and Gal4BD-TGN38 in the pGBT9
(TRP1) plasmid have been described previously (30, 31)
MATCHMAKER GAL4 Two-Hybrid System 3 (CLONTECH
Laboratories, Inc.) was used for the generation of GAL4BD-
mCD1d and yeast transformation. GAL4BD-mCD1d was gener-
ated by ligation of pGBKT7, the GAL4BD vector, with syn-
thetic double-strand DNA encoding the entire 10 aa cytoplasmic
domain of mCD1d. The construct was confirmed by sequenc-
ing. The Saccharomyces cerevisiae strain Y187 was transformed ac-
cording the manufacturer’s instruction with GAL4AD- 3A to-
gether with GAL4BD-mCD1d, GAL4BD-TGN38, or the
pGBKT7 vector, and selected in synthetic-defined medium
without leucine and tryptophan.  -galactosidase activities of
Y187 transformants in liquid culture were assayed using o-nitro-
phenyl- -d-galactopyranoside according the manufacturer’s in-
struction. Results are normalized by growth and cell numbers
used and expressed as the means   SD of three independent de-
terminations.
Surface Plasmon Resonance Analysis of AP-3 Binding to mCD1d
Cytoplasmic Tail Peptides. The interaction between mCD1d cy-
toplasmic tail peptides and the cytoplasmic adaptor complex AP-3
was determined in real time by surface plasmon resonance us-
ing a BIAcore 3000 biosensor (Biacore AB). Two peptides cor-
responding to WT mCD1d (CIWRRRSAYQDIR) and a mu-
tant tail peptide (CIWRRRSAAQDIR) in which the tyrosine
residue was substituted for alanine (in bold) were synthesized
with an NH2-terminal cysteine residue to allow their directed
immobilization via the Thiol group to a CM5 biosensor surface
(Biacore AB). The AP-3 complex was purified from pig brain
cytosol using chromatography through DEAE sepharose, hy-
droxyapatite, Mono-Q, and a final size-exclusion chromatogra-
phy step (unpublished data). The interaction experiments were
performed in buffer A (20 mM Hepes, 150 mM NaCl, 10 mM
KCl, 2 mM MgCl2, 0.2 mM DTT, pH 7.0) at a flow rate of 20
 l/min. The association phase, involving perfusion of AP-3 over
the biosensor, was recorded for 2 min, followed by dissociation
for 2 min with buffer A. A short pulse injection (15 s) of 20 mM
NaOH/0.5% SDS was used to regenerate the sensor chip surface
after each experimental cycle. AP-3 was used at protein concen-
trations ranging from 50 to 750 nM. To exclude distortions due
to injection and mixing, segments of the sensograms recorded
15–20 s after switching from buffer flow to adaptor solution or
5–10 s after switching back to running buffer, were used for the
calculations of association and dissociation rate, respectively.
Kinetic parameters and equilibrium dissociation constants
were determined from sensograms recorded at different adaptor
concentrations. The association constant ka, the dissociation con-
stant kd and the equilibrium constant KD  kd/ka were calculated
using Biacore kinetic evaluation software, assuming pseudo-first
order kinetics A   B   AB. The model calculates the association
rate constant, ka, and the steady-state response level, Req, by fit-
ting data to the equation R   Req(1-e [kaCn   kd][t   t0]), where t is
the time in seconds, Req is the steady-state response level, and
C the molar concentration of adaptors in the injection solution.
The steric interference factor n, which describes the valency of
the interaction between  A and VSR-PS1, was set to 1. The dis-
sociation rate constant, kd, was determined by fitting the data to
the equation R   R0e kd(t   t0), where R0 is the response level at
the beginning of the dissociation phase. This model has been ap-
plied recently to describe the interactions of adaptors with cyto-
solic domains (32–34) and is described in more detailed else-
where (35, 36).
Immunofluorescent Labeling and Confocal Microscopy.  Splenic
DCs were enriched by differential adherence and Percoll gradient
centrifugation as described previously (10). FSDC transfectants,
or spleen cells, were fixed, permeabilized, and blocked before the
addition of the antibodies as previously described (10, 22).
mCD1d molecules were labeled with biotinylated mAb 1B1 fol-
lowed by Cy3-conjugated streptavidin (Jackson Immuno-
Research Laboratories). For the colocalization experiments, cells
were stained with FITC-conjugated anti–mouse Lamp-2 mAb
(BD Biosciences). The fluorescently labeled cells were analyzed
with a Bio–Rad Laboratories MRC 1024 ES laser scanning con-
focal microscope.
Flow Cytometry.  Cells were washed once in PBS with 10%
FCS (staining buffer) and blocked in staining buffer containing
anti-Fc receptor antibody 2.4G2 (1:50) for 15 min at 4 C. Cells
were stained in 100  l vol with mAb to mCD1d, CD4, CD8 ,
NK1.1, TCR  , and CD11c, used at 1:100 in staining buffer at
4 C for 20 min. All primary antibodies were directly conjugated
to fluorophores and obtained from BD Biosciences. Cells were
analyzed on a FACScalibur (Becton Dickinson) cytometer.
V 14i NKT cells were stained with the mCD1d- GalCer tetra-
mers as described earlier (37). 
Antigen Presentation Assays. Glycosphingolipid antigens,
 GalCer, Gal (1→2) GalCer, and Gal (1→3) GalCer have
been described previously (22) and were a gift from the KirinT
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Pharmaceutical Research Corporation, Gunma, Japan. Antigen
presentation assays have been described previously (10, 22, 24,
38). APC used were either A20 cells transduced with WT
mCD1d or mutant constructs or whole splenocytes. Pearl and
heterozygous pe/  littermates were immunized subcutaneously
with 100  g of hen egg lysozyme (HEL) emulsified 1:1 in com-
plete Freund’s adjuvant (CFA; Difco Laboratories). After 10 d,
mice were killed and the draining LNs were removed. Cells were
resuspended in HL-1 medium (BioWhittaker) supplemented
with 100  g/ml streptomycin, 100 U/ml penicillin G (Life
Technologies), and cultured in 96-well plates at 4   105 cells per
well with the various concentrations of the immunodominant
peptide of HEL, p74–96. Proliferation was measured by addition
of 1  Ci of [3H]-thymidine (ICN, Inc.) and measurement of up-
take for the last 18 h of a 4-d culture.
BM Chimeras. BM cells were isolated from the femurs of
C57BL/6, B6 CD45.1 congenic, pe/ , and pe/pe mice, washed,
and magnetically depleted of Thy1.2-positive cells. 10 million
purified BM cells were coinjected into each recipient. Recipients
were either irradiated J 18 /  (1030 rads) or RAG1 /  (750
rads) mice. Chimeric animals were analyzed 10 wk after adoptive
transfer.
Results
mCD1d Localization to Lysosomes Is Required for Efficient
Glycolipid Presentation.  To determine how an altered dis-
tribution in the endosomal pathway might affect antigen
presentation, transfectants expressing chimeric molecules
with the mCD1d ectodomain were generated. Chimeric
molecules containing the transmembrane and cytoplasmic
domains of human CD1a (mCD1d/a) or the transmem-
brane domain of the mouse LDLr (mCD1d/ ldlr) (Fig. 1 a)
were predicted to be found predominantly in recycling
compartments or early endosomes. In the case of the LDL
receptor fusion, internalization should be mediated by
clathrin-dependent mechanisms (39, 40), whereas a differ-
ent mechanism governs internalization mediated by the
CD1a cytoplasmic tail (41). By contrast, CD1b is found
predominantly in late endosomes and lysosomes, and
therefore fusion of the mCD1d ectodomain to the trans-
membrane and cytoplasmic regions of human CD1b
(mCD1d/b) (Fig. 1 a) should cause expression of the chi-
meric protein in late endosomes or lysosomes and the cell
surface (12).
Fig. 1 b shows that A20 transfectants expressing high
levels of WT mCD1d and each of the three chimeric
mCD1d molecules were generated, although slightly
higher surface levels were obtained for cells expressing the
WT and the mCD1d/a chimera. The results from analysis
of intracellular distribution of these mCD1d molecules by
confocal microscopy were consistent with the expected
expression patterns. WT mCD1d colocalized extensively
with Lamp-2, as did the mCD1d/b chimera (Fig. 2). By
contrast, transfectants expressing the mCD1d/a fusion ex-
hibited a very predominant surface expression but rela-
tively little colocalization with Lamp-2. The mCD1d/ldlr
chimeric protein was found in intracellular vesicles that
are presumably recycling compartments, but like the
mCD1d/a fusion, it also had little colocalization with
Lamp-2 (Fig. 2). The antigen-presenting ability of the
chimeric mCD1d molecules was tested using V 14i NKT
cell hybridomas. Analogs of  GalCer that have additional
sugars linked to the 2  and/or 3  carbon of the galactose
cannot be recognized without internalization and carbo-
hydrate processing, which are required to generate the
monosaccharide  GalCer (22). mCD1d can bind to the
lipid portions of these analogs (22), but removal of
the outer sugar is required to allow for TCR recognition.
All of the mCD1d mutants could present  GalCer (Fig.
3), which does not require internalization and processing.
Their ability to do so, however, partially reflected the
level of surface expression, with the WT and mCD1d/a
chimera stimulating slightly higher levels of IL-2 release
Figure 1. Chimeric mCD1d molecules are ex-
pressed on the cell surface. (a) Constructs encoding
chimeric mCD1d molecules with the transmembrane
regions and cytoplasmic tails from either human CD1a
(mCD1d/a) or human CD1b (mCD1d/b) or the cyto-
plasmic tail of the mouse LDLr (mCD1d/ldlr) are
depicted. WT mCD1d sequences are indicated in
white rectangles and donor sequences for making the
mCD1d chimeras are indicated in stippled rectangles.
The entire cytoplasmic tail amino acid sequences are
shown, with potential adaptor binding motifs in bold
type, except for the mCD1d/ldlr chimera, which has a
longer cytoplasmic tail. In this case, only the sequence
motif important for endosomal localization is indicated.
(b) A20 transfectants with the indicated chimeric con-
structs were stained with PE-conjugated rat anti-
mCD1d mAb, and the expression level of surface
mCD1d molecules was analyzed by flow cytometry.
Isotype control stainings are shown with shaded fill
under the curve.T
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when pulsed with this compound. However, the
mCD1d/1a and mCD1d/ldlr chimeras had a greatly re-
duced capacity to present Gal (1→2) GalCer. This was
not observed for the mCD1d/b chimera. Although it has
a reduced level of surface mCD1d expression compared
with the mCD1d/a chimera (Fig. 1 b), mCD1d/b was
much better at presenting Gal( 1→2) GalCer (Fig. 3).
The data are consistent with the hypothesis that the local-
ization of mCD1d to late endosomes and/or lysosomes is
required for the efficient presentation of those glycosphin-
golipids that require internalization and carbohydrate pro-
cessing in lysosomes.
The Pearl Mutation Affects Antigen Presentation by mCD1d.
Data from the cells that express chimeric mCD1d mole-
cules described above demonstrated the importance of
mCD1d localization to late endosomes/lysosomes. Be-
cause AP-3 is involved in the lysosomal localization of
some proteins, we tested the ability of APC from AP-3 A
mutant pearl (pe/pe) mice to present the same glycolipid
antigens. As shown in Fig. 4, spleen cells from pe/pe mice
had a reduced ability to present two oligosaccharide ana-
logs of  GalCer that require internalization and process-
ing in lysosomes. Several findings indicate that this re-
duction was not due to differences in the cell populations
found in the spleen of pe/pe mice or to an inability to ex-
press mCD1d. First, we did not find decreased numbers
of DCs and B cells in the spleen of pe/pe mice (unpub-
lished data). Second,  GalCer could be presented by
pe/pe APC, indicative of a significant level of surface
mCD1d expression (Fig. 4). There was a partial reduc-
Figure 2. Chimeric mCD1d molecules
display differential intracellular localization.
FSDC transfectants expressing chimeric
mCD1d molecules were double labeled
with biotinylated anti-mCD1d followed by
Cy3-conjugated streptavidin and FITC-
conjugated Lamp-2 and analyzed by confocal
microscopy. The colocalization of the
mCD1d (red) and Lamp-2 (green) channels
is depicted with a yellow signal. Bars, 10  m.T
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tion in the immune response to  GalCer mediated by
pearl APC, but this was less pronounced than the re-
sponse to compounds that are dependent on internaliza-
tion and processing (Fig. 4).
Intracellular Distribution of mCD1d Is Altered in Pearl
Mice.  We tested for an alteration in surface expression of
mCD1d in cells from pearl mice using flow cytometry.
Surprisingly, despite decreased antigen-presenting ability,
increased levels of surface mCD1d were detected in sev-
eral cell types tested, including whole thymocytes (unpub-
lished data) and DCs from thymus and spleen (Fig. 5 a).
The findings of decreased antigen-presenting ability cou-
pled with increased surface mCD1d expression are remi-
niscent of those obtained from mice that express a form of
mCD1d missing its cytoplasmic tail due to a germ line
mutation (13). Therefore, we analyzed the intracellular
distribution of mCD1d in splenocytes from C57BL/6 and
pearl mice by confocal microscopy. Immunofluorescent la-
beling revealed extensive colocalization of mCD1d with
Lamp-2 in cells from WT mice (Fig. 5 b). In splenocytes
from  pearl mice, however, surface labeling with anti-
mCD1d mAb was prominent but there was considerably
less labeling of intracellular vesicles and reduced colocal-
ization with Lamp-2.
The Cytoplasmic Tail of mCD1d Interacts with the   Subunit
of AP-3. Lysosomal targeting of several proteins is ac-
complished by direct interaction of the tyrosine-based
motif located at their cytoplasmic tails with the   subunit
of the AP-3 complex (15). To determine if mCD1d em-
ploys the same mechanism for its lysosomal trafficking, we
used a yeast two-hybrid system to examine if the tyrosine
Figure 3. Chimeric mCD1d molecules not
found in late endosomes/lysosomes show reduced
antigen-presenting capacity. A20 cells expressing
WT or mutant mCD1d molecules were pulsed
with the indicated amounts of antigens, either
 GalCer or Gal (1→2)GalCer, washed, and
cultured with the 1.2 V 14i NKT cell hybrid-
oma. Cell-free supernatants were tested by
ELISA for IL-2 production. The error bars in-
dicate the SEM of triplicate measurements.
Similar results were obtained in four indepen-
dent experiments and also with the 1.4 and 3C3
V 14i NKT cell hybridomas (not depicted).
Figure 4. The AP-3 adaptor protein complex is important for antigen
presentation by mCD1d. Total spleen cells from pearl mice or hetero-
zygous littermates were pulsed with either Gal (1→2)GalCer,
Gal (1→3)GalCer, or  GalCer. The 1.2 V 14i NKT cell hybridoma
was cultured with the pulsed APC, and IL-2 release was measured. The
response of the 3C3 hybridoma was similar (not depicted). The experi-
ments were repeated with APC from three different sets of mice.
Table I. Biophysical Parameters of AP-3 Complex Binding to WT 
and Tyrosine Mutant Peptides from the mCD1d Cytoplasmic Tail
ka (1/M   s) kd (1/s) KD   kd/ka ( M)
WT 8.9   103 4.8   10 3 0.54
Y   A 1.9   103 5.0   10 3 2.63T
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motif in the cytoplasmic tail of mCD1d interacts with the
AP-3   subunit. As shown in Fig. 5 c, the interaction is
evident by the expression of  -galactosidase activity of
yeast transformants containing both the AP-3   subunit
and the mCD1d cytoplasmic tail. This interaction appears
to be even stronger than that between the AP-3   subunit
with the TGN38 cytoplasmic tail construct, the positive
control.
We also used surface plasmon resonance to measure the
interaction of synthetic peptides corresponding to the cy-
toplasmic tail of WT mCD1d and a variant in which the
tyrosine residue was substituted for alanine, to purified
AP-3. AP-3 bound to the WT tail with an equilibrium-
binding constant of 540 nM (Table I). Binding was de-
creased by almost fivefold when AP-3 was passed over the
mutant CD1d peptide (Y   A), due to a decreased on
rate. This demonstrates that optimal AP-3 binding to
CD1d requires a functional tyrosine motif (YQDIR). The
specificity of the AP-3 binding to the mouse CD1d cyto-
plasmic tail was further corroborated by competition ex-
Figure 5. The AP-3 adaptor protein complex is important for trafficking
of mCD1d. (a) Increased levels of mCD1d were detected by flow cytometry
on the surface of DCs from the thymus (left) and spleen (right) from pearl
mice. Representative data from four experiments. (b) Confocal microscopy
on spleen cells from pearl mice. Spleen cells from B6 or pearl enriched for
DCs were double labeled with anti-mCD1d and Lamp-2 as described
above and analyzed by confocal microscopy. Magnification is 144 . (c)
Binding of mCD1d to the   subunit of the adaptor complex AP-3. Yeast
cells were transformed with the GAL4AD- 3A along with GAL4BD-
mCD1d, GAL4BD-TGN38 (as a positive control), or pGBKT7 vector
only (as a negative control).  -Galactosidase activities were assayed to
quantify specific interactions. Results are representative of four independent
experiments and expressed as the mean of  -galactosidase units   SD of
three independent determinations.T
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periments in which AP-3 was preincubated with a 10- to
50-fold molar excess of soluble peptides corresponding to
the mouse and human CD1d tyrosine motifs. Whereas
preincubation of AP-3 with the soluble mouse CD1d
peptide completely inhibited subsequent binding to the
immobilized mouse CD1d cytoplasmic tail sequence on
the biosensor surface, we could not detect any effect by
preincubating AP-3 with a soluble human CD1d peptide
(unpublished data). This is consistent with previous data
indicating that human CD1d does not interact with AP-3
(34), and it highlights both the specificity of this interac-
tion and a major difference between human and mouse
CD1d.
V 14i NKT Cells Are Decreased in Pearl Mice.  In mice
that have a germline deletion in the cytoplasmic tail of
mCD1d, the number of V 14i T cells is greatly dimin-
ished (13). We therefore determined if there was a similar
decrease in AP-3–deficient pearl mice. There was a marked
reduction in the percentage (Fig. 6 a) and absolute number
(Fig. 6 b) of V 14i NKT cells in thymus, spleen, and liver,
ranging up to approximately fivefold. Consistent with this
decreased cell number, the in vivo response to  GalCer
was also strongly reduced (unpublished data). The results
from intracellular cytokine staining, however, indicated
that the residual V 14i NKT cell population was capable
of responding to  GalCer by producing cytokines (un-
published data).
The decreased numbers of V 14i NKT cells in pearl
mice could be caused by enhanced negative selection due
to the increased levels of surface mCD1d expression (Fig.
5 a). We tested this possibility by analyzing BM chimeras
that received T cell–depleted BM from CD45.1 congenic
C57BL/6 mice along with marrow from either pearl mice
or their heterozygous littermates. The recipients were ei-
ther irradiated J 18 /  mice or RAG-1 /  mice, both of
which do not have cells that stain with the  GalCer/
mCD1d tetramer. Fig. 7 a shows that BM cells from both
donors contributed to the pool of V 14i NKT cells de-
tected in the liver of the recipient mice 10 wk after transfer.
Although cells from the CD45.1 congenic C57BL/6 donor
always contributed the majority of the V 14i NKT cell
population, there was no difference in the percentage of
tetramer  cells originating from pearl homozygous and het-
erozygous donors. Based on this result, we conclude that
the requirement for AP-3 expression is not cell autono-
mous, i.e., AP-3 expression is not required in either the
V 14i NKT cell itself or its precursor. A detailed compari-
son of the total number of V 14i NKT cells (including
both donors) in different organs of the chimeric recipients
is compiled in Fig. 7 b. There is no decrease in the V 14i
NKT cell number when the cotransferred BM cells were
from pearl mice. This suggests that the increased level of
surface mCD1d expression on thymocytes and other cell
types derived from the pearl donor did not cause negative
selection of V 14i NKT cells.
The Phenotype of Mocha Mice Is Similar to Pearl Mice.
We also analyzed the mocha (mh/mh) strain of mice, which
lack AP-3 function due to a mutation in a different sub-
unit, AP-3 , which results in the complete loss of this
subunit (23). As shown in Fig. 8 a, similar to pe/pe mice,
there were increased surface levels of mCD1d expression
on thymocytes from mocha mice compared with the het-
Figure 6. Pearl mice have reduced V 14i T cells. (a)
The liver and thymus of pearl and heterozygous control
mice was measured by flow cytometry on cells stained
with the  GalCer-mCD1d tetramer and a mAb to the
TCR   chain. The percentages indicated are the averages
obtained from all the mice tested. (b) Compilation of
the absolute numbers of V 14i NKT cells, detected as
 GalCer/mCD1d tetramer  and TCR    cells. n,
number of mice tested. The horizontal bar indicates
the mean value of the cell number.T
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erozygous controls. Spleen cell levels of mCD1d were
heterogeneous, but an increase in surface mCD1d expres-
sion also was observed (Fig. 8 a). Furthermore, mocha
mice had a greatly reduced number of V 14i NKT cells
(Fig. 8 b), whereas CD4  T cells numbers were not al-
tered (unpublished data). Additionally, presentation of
glycolipid antigens that require internalization and pro-
cessing to V 14i NKT cell hybridomas is reduced using
APC from mocha mice (unpublished data). Overall, the
data demonstrate that mice with defects in either AP-
3 3A or AP-3  have a similar phenotype with respect to
mCD1d-mediated antigen presentation and V 14i NKT
cell development.
The CD1d and MHC Class II Trafficking Pathways Are
Different. The defect in AP-3–defective pearl mice might
lead to a disruption of vesicular traffic that could alter
MHC class II trafficking, which might diminish the func-
tion of conventional CD4  and V 14i NKT cells. How-
ever, flow cytometry analysis indicated that the number of
CD4  T cells was not decreased in the spleen and thymus
of pearl mice (Fig. 9 a and unpublished data). Also, the
proportion of CD4  T cells in the spleen with a pheno-
type typical of recently activated/memory cells was not
different when pearl mice and pe/  controls were com-
pared (Fig. 9 a).
To assess antigen presentation function, mice were
primed with HEL, and the recall proliferative response of T
cells in the draining LN to the dominant HEL peptide
(p74–96) presented by the I-Ab class II molecule was mea-
sured. As shown in Fig. 9 b, T cells from pearl mice were
capable of making a normal CD4 T cell proliferative re-
sponse, the difference between pearl and pe/  mice was
not statistically significant (P   0.13). Therefore, there is
no evidence for a global or severe deficiency in conven-
Figure 7. Increased surface
mCD1d expression does not cause
deletion of V 14i NKT cells in
pearl mice. (a) The percent
tetramer  cells in the livers of
J 18 /  recipients of the indicated
types of BM are depicted.
Tetramer  cells were gated and
analyzed for expression of CD45.1,
indicating derivation from the
C57BL/6 donor. Cotransferred
CD45.1-negative (CD45.2 ) cells
were derived from either the pe/ 
donors (left) or the pe/pe donors
(right). Representative data from
one of two experiments are
shown. (b) The total number of
donor-derived V 14i NKT cells
in the liver (L), spleen (S), and thy-
mus (T) of the indicated recipients.
Figure 8. Mocha mice have elevated surface
mCD1d levels and reduced V 14i NKT cells.
(a) Measurement of surface levels of mCD1d by
flow cytometry on whole thymocytes and total
splenocytes from mocha mice and control het-
erozygous mice. (b) The liver, spleen, and thymus
of mocha mice have significantly reduced per-
centages (not depicted) and absolute numbers
of V 14i NKT cells. Comparison of the absolute
numbers of V 14i NKT cells from mh/mh and
mh/  control mice. n, number of mice tested.
The horizontal bar indicates the mean value of
the cell number.T
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tional MHC class II–reactive, CD4 T cells in the absence
of AP-3 function.
The invariant chain (Ii) is important for the endosomal
localization of MHC class II molecules (42), and a bio-
chemical association between Ii and CD1d has been re-
ported (43). To further compare the pathways leading to
MHC II and CD1d antigen presentation, we analyzed the
development of V 14i NKT cells and APC function in
invariant chain knockout (Ii / ) mice. As reported previ-
ously (44), mCD1d surface expression in the thymus of
Ii /  mice is similar to C57BL/6J control mice, whereas
mCD1d surface expression in the spleen of Ii /  mice is
increased (unpublished data). The lack of Ii, however, did
not alter the percentage or the total number of V 14i
NKT cells in thymus and liver (Fig. 10 a). Furthermore, as
shown in Fig. 10 b, splenocytes from Ii /  mice showed
no reduction in their ability to present the glycolipid anti-
gens   GalCer and Gal (1→2) GalCer to V 14i NKT
cell hybridomas. The greater response mediated by Ii / 
splenic APC could reflect the higher surface levels of
mCD1d or perhaps a positive effect of the absence of Ii on
glycosphingolipid antigen presentation.
Figure 9. Conventional CD4  T cells are
normal in pearl mice. (a) Comparison of the
number of naive and memory CD4  T cells in
the spleen of pearl and heterozygous control
mice as measured by flow cytometry. (b) Pearl
and control mice were primed with HEL and
the response of CD4  T cells from draining
LNs to the indicated concentrations of the
immunodominant peptide of HEL were mea-
sured. The data are the average of five sets of
mice.
Figure 10. V 14i NKT cell number and mCD1d antigen presentation
are normal in Ii    mice. (a) The thymus, spleen, and liver of Ii /  mice
were analyzed by flow cytometry on cells stained with the  GalCer-
mCD1d tetramer and a mAb to the TCR   chain. The percentages indicated
are the averages from the mice (n   4) tested. (b) The 1.2 hybridoma was
cultured with total spleen cells from C56BL/6J and Ii /  mice in the
presence of the indicated antigens, and IL-2 release was measured as
described in experimental procedures. The error bars indicate the SEM of
triplicate measurements. Similar results were obtained in three different
sets of mice in independent experiments and also with the 1.4 and 3C3
hybridomas (not depicted).T
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Discussion
The pathway leading to the presentation of glycolipid
antigens by CD1 molecules is just beginning to be eluci-
dated. Although the importance of the endosomal local-
ization of different CD1 molecules is now well established
(41), the relative importance of different types of endo-
somes for CD1d presentation has not been determined.
Here, using chimeric molecules we showed that the type
of endosomal compartment that mCD1d localizes to is
critical for the effective presentation of some antigens. The
mCD1d/b chimera was very efficient at presentation of
glycolipid antigens that require processing, suggesting that
the processing event and the loading of mCD1d both oc-
cur in late endosomal or lysosomal vesicles. The striking
difference in the ability of the CD1d/b and CD1d/a chi-
meras to present these antigens is consistent with previous
experiments on CD1a and CD1b (41, 45, 46) and with the
hypothesis that the different human CD1 isoforms are
adapted to survey different types of endosomes (41). Mice
lack CD1a, CD1b, and CD1c homologues. As a result, it
is possible that mCD1d may need to survey multiple vesic-
ular compartments, and in fact, it is found in early and late
endosomes (44).
Consistent with experiments implicating a requirement
for mCD1d localization to late endosomes or lysosomes,
we showed that the function of the adaptor protein AP-3
is required for the efficient presentation of glycolipid anti-
gens that require internalization and processing. The anal-
ysis of strains of mice having spontaneous mutations for
either the  3A or the   subunits confirms that AP-3 defi-
ciency is responsible for defects in mCD1d-mediated rec-
ognition and V 14i NKT cell selection, as opposed to
some other genetic change that might have occurred in
these strains. The response to  GalCer also was decreased
when AP-3–deficient APC were tested but to a lesser ex-
tent. This is consistent with the view that presentation of
this antigen can occur after surface loading of mCD1d
molecules at neutral pH, although optimal  GalCer pre-
sentation may occur only after internalization and loading
of mCD1d molecules in endosomal compartments (9, 10,
22). It is important to note that the decrease in antigen
presentation occurred despite increased levels of surface
mCD1d expression by spleen cells, including DC, from
the mutant mice.
While this article was in preparation, it was shown that
human CD1b also requires AP-3 function for intracellular
localization and for antigen presentation in vitro (47).
However, human CD1d did not require AP-3 (47), a result
we corroborated here in a competition-binding experi-
ment. Although the two CD1d homologues both contain a
YXX  motif (where X is any amino acid and   is one
having a bulky, hydrophobic side chain), the cytoplasmic
tail of human CD1d is significantly different from that of
the mouse. Therefore, subtle changes in the sequence of
the YXX  motif are important, and the ability of human
CD1d to bind adaptors and to localize to specific compart-
ments is likely to be different from mCD1d.
Interestingly, AP-3–deficient mice also showed reduced
numbers of V 14i NKT cells. The results from analysis of
mixed BM chimeras indicated that AP-3 expression is not
required in the V 14i NKT cell itself, and the reduced
cell numbers are not due to negative selection. The data
are consistent with the hypothesis that the intact mCD1d
cytoplasmic tail must interact with AP-3 in order to effi-
ciently load the natural glycolipid ligand that selects
V 14i NKT cells and, furthermore, that the types of
events governing the processing and mCD1d loading of
synthetic compounds, such as Gal (1→2) GalCer, and
the loading of the elusive natural ligand exhibit similar re-
quirements. Although these are logical conclusions, they
remain speculative inferences in the absence of knowledge
about the nature of the endogenous ligand(s) driving the
development and expansion of V 14i NKT cells. Inter-
estingly, the magnitude of the decrease in V 14i NKT
cell number is similar to the decrease in mice bearing a
germ line mutation in mCD1d that removes the tyrosine-
containing cytoplasmic tail (13). These data suggest that
the essential in vivo function of the mCD1d cytoplasmic
tail sequence is likely to be mediated in part by AP-3, al-
though an in vivo role for other AP complexes in CD1d
trafficking is not excluded. However, in both the AP-3
and cytoplasmic tail mutants the defect is not complete,
and the residual cells are functional, suggesting a minor,
AP-3– and mCD1d cytoplasmic tail–independent path-
way for mCD1d to influence the differentiation of the
V 14i NKT cell population.
The results from previous pulse–chase labeling studies
indicated that mCD1d arrives rapidly at the cell surface, is
then internalized, and undergoes several rounds of subse-
quent recycling between the cell surface and endosomes
(44). Human CD1b might follow a similar pathway (48).
mCD1d molecules eventually accumulate in lysosomes, al-
though this process takes several hours (44). Collectively,
these findings suggest that the mCD1d molecules impor-
tant for presentation of the synthetic glycosphingolipids,
and perhaps the natural ligand as well, are relatively mature
molecules that may have undergone several rounds of recy-
cling, and potentially, several rounds of exchange of gly-
colipid antigens before localizing to lysosomes. However, it
remains possible that a subpopulation of newly synthesized
mCD1d molecules travels from the Golgi network directly
to late endosomes or lysosomes.
CD1 proteins and MHC class II molecules are both
found in endosomes, and most of the previously published
work on CD1 antigen presentation has emphasized similar-
ities to the MHC class II pathway. For example, CD1b
molecules were reported to be present in the MIIC (12,
49), and human CD1d was reported to be associated with
MHC class II (43). Deficiencies in the cathepsins responsi-
ble for Ii degradation have effects on V 14i NKT cells
and/or CD1d function. Cathepsin L is required for V 14i
NKT cell differentiation (50), and in one report cathepsin S
was reported to alter both the intracellular trafficking ofT
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mCD1d and its ability to present synthetic glycolipid anti-
gens (51). However, the authors considered it most likely
that this phenotype in cathepsin S–deficient mice was an
indirect effect on the biogenesis of endosomal compart-
ments due to reduced catabolism of Ii. Furthermore, it was
reported recently that mCD1d is associated with Ii during
its biosynthesis and that the autoreactivity of V 14i NKT
cells for mCD1d is reduced when Ii-deficient APCs were
used to stimulate them (44). Based on these results, it was
suggested that Ii might play a role in blocking the mCD1d
groove in the ER, similar to one of its roles in MHC class
II presentation (42). However, our data indicate that the
effects of Ii deficiency on V 14i NKT cells are much less
dramatic than the effects on conventional CD4  T cells.
The lack of Ii apparently does not prevent loading of the
natural ligand that selects V 14i NKT cells, nor does it
prevent the loading of antigens that require internalization
and processing in late endosomes.
The data presented here clearly highlight the differences
in the pathways required for the localization to late endo-
somes/lysosomes of mCD1d and MHC class II and the ac-
cessory molecules required for their optimal antigen-pre-
senting function. This is evidenced by the difference in
magnitude of the influence of Ii and the requirement for
AP-3 function. Here we showed that the number and
phenotype of CD4  T cells and the CD4  T cell response
to a model protein antigen are not affected by the absence
of AP-3. Consistent with this, it was reported recently that
the localization and catabolism of Ii and the route of MHC
class II-Ii transport are not altered in the absence of AP-3
(52, 53), correlating with the lack of interaction between Ii
and AP-3 (54). Therefore, although it remains possible that
AP-3–directed trafficking is needed for some class II–depen-
dent immune responses, this cannot be true in the majority
of cases. However, the requirement for AP-3 function in
mCD1d presentation suggests the intriguing possibility that
there could be additional molecules that play a role specifi-
cally in CD1-dependent pathways of antigen presentation.
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